标题：Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study

中文标题：安尼妥单抗联合白蛋白结合型多西他赛用于 HER2 阳性晚期乳腺癌患者：一项随机Ⅲ期研究

讲者：徐兵河  中国医学科学院肿瘤医院

标题：HER2-PET imaging to predict trastuzumab deruxtecan (T-DXd) efficacy in advanced breast cancer: The phase II PREDICT-HER trial

中文标题：HER2-PET显像预测晚期乳腺癌患者德曲妥珠单抗（T-DXd）疗效：Ⅱ期PREDICT-HER研究

讲者：金娟  复旦大学附属肿瘤医院 

标题：APEX-Breast01: TQB2102 versus chemotherapy in HER2-low recurrent or metastatic breast cancer (r/m BC) : Results from a randomized phase 3 study

中文标题：APEX-Breast01：TQB2102对比化疗用于 HER2 低表达复发或转移性乳腺癌（r/m BC）：一项随机Ⅲ期研究结果

讲者：王树森  中山大学肿瘤防治中心

标题：Final OS analysis of sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: Phase III OptiTROP-Breast01

中文标题：芦康沙妥珠单抗（sacituzumab tirumotecan）对比化疗用于既往接受过治疗的局部复发或转移性三阴性乳腺癌的最终总生存期分析：Ⅲ期OptiTROP-Breast01研究

讲者：李曼 大连医科大学附属第二医院

标题：Target switching with conserved-payload novel ADCs in patients with metastatic breast cancer following prior ADC therapy (SWITCH): a prospective, open-label, phase 2 platform trial

中文标题：在既往接受过ADC治疗的转移性乳腺癌患者中，采用载荷相同的新型ADC进行靶点切换（SWITCH）：一项前瞻性、开放标签、Ⅱ期平台试验

讲者：Lei Fan (Shanghai, China)

标题：Safety and efficacy of SYS6043, a Novel B7-H3–Targeting Antibody-Drug Conjugate, in Patients with Advanced breast cancer

中文标题：SYS6043（一种新型靶向B7-H3的抗体药物偶联物）在晚期乳腺癌患者中的安全性和疗效

讲者：王红霞  复旦大学附属肿瘤医院

标题：Bulumtatug Fuvedotin (BFv, 9MW2821), a Nectin-4–Directed Antibody-Drug Conjugate (ADC), in Patients with Locally Advanced or Metastatic Triple Negative Breast Cancer (la/mTNBC) Previously Treated with Topoisomerase I Inhibitor (TopI)-Based ADCs: Results from a Phase 2 Study

中文标题：Bulumtatug Fuvedotin（BFv，9MW2821），一种靶向Nectin-4的抗体药物偶联物（ADC），用于既往接受过基于拓扑异构酶Ⅰ抑制剂（TopⅠ）的ADC治疗的局部晚期或转移性三阴性乳腺癌（la/mTNBC）患者：一项Ⅱ期研究结果

讲者：张剑  复旦大学附属肿瘤医院